Tenascin C Antibody [Biotin]

• Reactivity: Hu
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Biotin
• Concentration: LYOPH

Tenascin C Antibody [Biotin] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Tenascin C
  Ser186-Pro625
  Accession # BAG64930
• Specificity: Detects human Tenascin C in Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: TNC
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.1 ug/mL
• Readout System:
  • Streptavidin Native Protein NBP2-29367
  • Streptavidin Native Protein NBP2-29370
  • Streptavidin Native Protein NBP2-29371

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Tenascin C Antibody [Biotin]

• 150-225
• Cytotactin
• Glioma-associated-extracellular matrix antigen
• GMEM
• GP 150-225
• hexabrachion (tenascin C, cytotactin)
• hexabrachion (tenascin)
• Hexabrachion
• HXB
• HXBcytotactin
• JI
• MGC167029
• Myotendinous antigen
• neuronectin
• Tenascin C
• Tenascin J1
• tenascin
• tenascin-C isoform 14/AD1/16
• Tenascin-C
• TNC
• TN-C
• TNGP

Background

Tenascin C, also known as hexabrachion, cytotactin, neuronectin, GMEM, JI, myotendinous antigen, glioma-associated-extracellular matrix antigen, and GP 150‑225, is a member of the Tenascin family of extracellular matrix proteins. It is secreted as a disulfide-linked homohexamer whose subunits can vary in size from approximately 200 kDa to over 300 kDa due to differences in glycosylation (1). Rotary-shadowed electron micrographs of the purified molecule show six strands joined to one another at one end in a globular domain with each arm terminating in a knob-like structure (2, 3). The human Tenascin C monomer is synthesized as a precursor with a 22 amino acid (aa) signal sequence and a 2179 aa mature chain. The mature chain consists of a coiled-coil region (aa 118‑145), followed by 15 EGF‑like domains, 15 fibronectin type-III domains, and a fibrinogen C-terminal domain. In addition, there are 23 potential sites of N-linked glycosylation. Alternative splicing within the fibronectin type-III repeats produces six isoforms for human Tenascin C. Mature human Tenascin C (isoform 1) shares 84% aa sequence identity with mature mouse Tenascin C. In the developing embryo, Tenascin C is expressed during neural, skeletal, and vascular morphogenesis (1, 2). In the adult, it virtually disappears with continued basal expression detectable only in tendon-associated tissues (1, 2). However, great up‑regulation in expression occurs in tissues undergoing remodeling processes seen during wound repair and neovascularization or in pathological states such as inflammation or tumorigenesis (1, 4, 5). Biologically, Tenascin C functions as an adhesion-modulatory extracellular matrix protein (1, 4‑8). Specifically, it antagonizes the adhesive effects of fibronectin, and impacts the ability of fibroblasts to deposit and contract the matrix by affecting the morphology and signaling pathways of adherent cells (5‑7). Tenascin C acts by blocking syndecan-4 binding at the edges of the wound and by suppressing fibronectin-mediated activation of RhoA and focal adhesion kinase (FAK) (4‑8). Tenascin C thus promotes epidermal cell migration and proliferation during wound repair.

1. Hsia, H.C. and J.E. Schwarzbauer (2005) J. Biol. Chem. 280:26641.
2. Nies, D.E. et al. (1991) J. Biol. Chem. 266:2818.
3. Erickson, H.P and J.L. Iglesias (1984) Nature 311:267.
4. Orend, G. et al. (2003) Oncogene 22:3917.
5. Wenk, M.B. et al. (2000) J. Cell Biol. 150:913.
6. Midwood, K.S. et al. (2004) Mol. Biol. Cell 15:5670.
7. Midwood, K.S. and J. E. Schwarzbauer (2002) Mol. Biol. Cell 13:3601.
8. Hsia, H.C. and J.E. Schwarzbauer (2006) J. Surg. Res. 136:92.

 

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Tenascin C Antibody (BAF3358)(2)

Publications using BAF3358

• Martin L. Decaris, Kelvin W. Li, Claire L. Emson, Michelle Gatmaitan, Shanshan Liu, Yenny Wang et al. Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood Hepatology 2017-01-01 [PMID: 27706836]
• Bellini A, Marini MA, Bianchetti L, Barczyk M, Schmidt M, Mattoli S Interleukin (IL)-4, IL-13, and IL-17A differentially affect the profibrotic and proinflammatory functions of fibrocytes from asthmatic patients. Mucosal Immunol, 2011-12-21;5(2):140-9. 12/21/2011 [PMID: 22189956]

FAQs for Tenascin C Antibody (BAF3358). (Showing 1 - 1 of 1 FAQs).

1. One of our clients is looking for antibodies against tenascin C and fibronectin that could be used for FFPE rat tissues. These antibodies should exclusively recognize tenascin C and fibronectin and do not cross react with each other. Can you inform me if you have these antibodies?
   • Here is a link to Tenascin C antibodies we have validated in rat tissues for IHC-P Here are antibodies we have validated in fibronectin in rat tissues for IHC-P

Bioinformatics

• Gene Symbol: TNC
• Uniprot:
  • BAG64930()